Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKAB2 | O43741 | 1/20 | 1.00 |
| ▸ | PRKAG1 | P54619 | 1/20 | 1.00 |
| ▸ | PRKAA2 | P54646 | 1/20 | 1.00 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 1.00 |
| ▸ | PRKAG3 | Q9UGI9 | 1/20 | 1.00 |
| ▸ | PRKAG2 | Q9UGJ0 | 1/20 | 1.00 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.48 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.48 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.48 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | NPY1R | P25929 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29611296 | 1.00 | PRKAB2 (1.00) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL716606 | 1.00 | PRKAB2 (1.00) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL19236034 | 1.00 | PRKAB2 (1.00) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL19630453 | 0.93 | PRKAB2 (0.87) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL20880463 | 0.92 | PRKAB2 (0.85) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL10001663 | 0.92 | PRKAB2 (0.85) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL14922196 | 0.91 | PRKAB2 (0.83) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL20663726 | 0.90 | PRKAB2 (0.81) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL20663730 | 0.90 | PRKAB2 (0.81) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL19236026 | 0.84 | PRKAB2 (0.73) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11324768-B2 | Applications of triacetyl-3-hydroxyl phenyl adenosine in treating vascular inflammations or improving vascular endothelium functions | JIANGSU TASLY DIYI PHARMACEUTICALS CO., LTD. (CN) | 2022-05-10 | — | — | US | disclosed |
| US-11058703-B2 | Application of triacetyl-3-hydroxyphenyladenosine in preparation of pharmaceutical drug for preventing or treating non-alcoholic fatty liver disease | JIANGSU TASLY DIYI PHARMACEUTICAL CO., LTD. (CN) | 2021-07-13 | — | — | US | disclosed |
| US-20200316101-A1 | APPLICATIONS OF TRIACETYL-3-HYDROXYL PHENYL ADENOSINE IN TREATING VASCULAR INFLAMMATIONS OR IMPROVING VASCULAR ENDOTHELIUM FUNCTIONS | Beijing Gushen Life Health Technology Co., Ltd. (CN) | 2020-10-08 | — | — | US | disclosed |
| EP-3466433-A1 | APPLICATIONS OF TRIACETYL-3-HYDROXYL PHENYL ADENOSINE IN TREATING VASCULAR INFLAMMATIONS OR IMPROVING VASCULAR ENDOTHELIUM FUNCTIONS | Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. (CN) | 2019-04-10 | — | — | EP | disclosed |
| US-20190070208-A1 | USE OF TRIACETYL-3-HYDROXYPHENYLADENOSINE IN PREPARING PHARMACEUTICALS FOR TREATMENT OF ATHEROSCLEROSIS | JIANGSU TASLY DIYI PHARMACEUTICAL CO LTD (CN) | 2019-03-07 | — | — | US | disclosed |
| US-20190022120-A1 | APPLICATION OF TRIACETYL-3-HYDROXYPHENYLADENOSINE IN PREPARATION OF PHARMACEUTICAL DRUG FOR PREVENTING OR TREATING NON-ALCOHOLIC FATTY LIVER DISEASE | Beijing Gushen Life Health Technology Co., Ltd. (CN) | 2019-01-24 | — | — | US | disclosed |
| EP-2407474-B1 | TRIACETYL-3-HYDROXYPHENYLADENOSINE AND ITS USE FOR REGULATING BLOOD FAT | INST MATERIA MEDICA CAMS (CN) | 2013-08-14 | — | — | EP | disclosed |
| US-8435962-B2 | Triacetyl-3-hydroxyphenyladenosine and its use for regulating blood fat | INSTITUTE OF MATARIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) | 2013-05-07 | — | — | US | disclosed |
| US-8435962-B2 | Triacetyl-3-hydroxyphenyladenosine and its use for regulating blood fat | INSTITUTE OF MATARIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) | 2013-05-07 | — | — | US | disclosed |
| US-20120053143-A1 | TRIACETYL-3-HYDROXYPHENYLADENOSINE AND ITS USE FOR REGULATING BLOOD FAT | INSTITUTE OF MATARIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) | 2012-03-01 | — | — | US | disclosed |
| US-20120053143-A1 | TRIACETYL-3-HYDROXYPHENYLADENOSINE AND ITS USE FOR REGULATING BLOOD FAT | INSTITUTE OF MATARIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) | 2012-03-01 | — | — | US | disclosed |
| EP-2407474-A1 | TRIACETYL-3-HYDROXYPHENYLADENOSINE AND ITS USE FOR REGULATING BLOOD FAT | INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) | 2012-01-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11058703-B2 | Application of triacetyl-3-hydroxyphenyladenosine in preparation of pharmaceutical drug for preventing or treating non-alcoholic fatty liver disease | AADAT, LIPC, GOT1 | PRKAB2 308/4885PRKAG1 213/4885PRKAA2 359/4885 |
| US-20190022120-A1 | APPLICATION OF TRIACETYL-3-HYDROXYPHENYLADENOSINE IN PREPARATION OF PHARMACEUTICAL DRUG FOR PREVENTING OR TREATING NON-ALCOHOLIC FATTY LIVER DISEASE | AADAT, LIPC, GOT1 | PRKAB2 308/4885PRKAG1 213/4885PRKAA2 359/4885 |
| US-20190070208-A1 | USE OF TRIACETYL-3-HYDROXYPHENYLADENOSINE IN PREPARING PHARMACEUTICALS FOR TREATMENT OF ATHEROSCLEROSIS | ADORA3, ADORA2A, AMPD3 | PRKAB2 114/4885PRKAG1 63/4885PRKAA2 308/4885 |
| US-20120053143-A1 | TRIACETYL-3-HYDROXYPHENYLADENOSINE AND ITS USE FOR REGULATING BLOOD FAT | ADORA3, ADORA2A, ADORA1 | PRKAB2 678/4885PRKAG1 496/4885PRKAA2 660/4885 |
| US-11324768-B2 | Applications of triacetyl-3-hydroxyl phenyl adenosine in treating vascular inflammations or improving vascular endothelium functions | LIPG, ADORA2A, VCAM1 | PRKAB2 95/4885PRKAG1 128/4885PRKAA2 299/4885 |
| US-20200316101-A1 | APPLICATIONS OF TRIACETYL-3-HYDROXYL PHENYL ADENOSINE IN TREATING VASCULAR INFLAMMATIONS OR IMPROVING VASCULAR ENDOTHELIUM FUNCTIONS | ADORA2A, LIPG, VCAM1 | PRKAB2 80/4885PRKAG1 85/4885PRKAA2 165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.